Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Fallopian Tube Neoplasms 7Ovarian Neoplasms 6Breast Neoplasms 4Multiple Myeloma 3Lymphoma 3Sarcoma, Kaposi 2Neoplasms 2Multi-centric Castleman's Disease 2Leukemia 2Hodgkin Disease 2Triple Negative Breast Neoplasms 1Subcutaneous panniculitis-like T-cell lymphoma 1Sarcoma, Synovial 1Sarcoma 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Platinum-Refractory Fallopian Tube Carcinoma 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Macular dystrophy, corneal type 1 1Lymphoproliferative Disorders 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Primary Effusion 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell 1Lymphoma, AIDS-Related 1Lymphadenopathy 1

Interventions

trametinib 1liposomal doxorubicin 1Topotecan 1Taxes 1Tamoxifen 1Specimen Handling 1Paclitaxel 1Nivolumab 1Magnetic Resonance Spectroscopy 1Letrozole 1Ipilimumab 1Doxorubicin 1CTLA-4 Antigen 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Cystadenocarcinoma, Serous × liposomal doxorubicin × Clear all
NCT02101788 2025-11-13

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

National Cancer Institute (NCI)

Phase 2/3 Completed
260 enrolled 20 charts

Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡